SCHEMBL17134556

SCHEMBL17134556

Cc1c(Cl)ncc(C(=O)O)c1NCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.52
▸ ASPH Q12797 2/20 0.52
▸ KDM8 Q8N371 2/20 0.52
▸ RIOX2 Q8IUF8 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ SRC P12931 1/20 0.47
▸ KDM6B O15054 1/20 0.47
▸ KDM4A O75164 1/20 0.47
▸ KDM4D Q6B0I6 1/20 0.47
▸ KDM4C Q9H3R0 1/20 0.47
▸ RAB9A P51151 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.44
▸ MAPT P10636 3/20 0.44
▸ LMNA P02545 2/20 0.44
▸ HPGD P15428 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ KDM5B Q9UGL1 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17135165 0.86 NPSR1 (0.62) KDM4ERAB9ANPSR1ALDH1A1MAPT
SCHEMBL17134738 0.86 KDM4E (0.55) KDM4EASPHKDM8RIOX2ATM
SCHEMBL17135121 0.80 KDM4E (0.48) KDM4EASPHKDM8RIOX2ATM
SCHEMBL17134687 0.76 SCN5A (0.40) KDM4EATMRAB9AALDH1A1MAPT
SCHEMBL17134582 0.76 MEN1 (0.48) MAPTLMNAHPGDTDP1ADORA3
SCHEMBL17134663 0.75 KDM4E (0.55) KDM4EASPHKDM8RIOX2ATM
SCHEMBL17134512 0.75 CHRM4 (0.44) KDM4EATMRAB9AALDH1A1MAPT
SCHEMBL27303481 0.74 KDM4E (0.47) KDM4EASPHKDM8RIOX2ATM
SCHEMBL32671624 0.73 RAB9A (0.74) KDM4EASPHKDM8RIOX2ATM
SCHEMBL4409419 0.72 KDM4E (0.60) KDM4EASPHKDM8RIOX2ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2927214-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-03-21 — — EP disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 — — US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 — — US disclosed
EP-2927214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2015-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ARG1, H1-0, TYR KDM4E 1474/4885ASPH 712/4885KDM8 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback